EKZ-001 is under clinical development by Eikonizo Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EKZ-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EKZ-001 overview
EKZ-001 is under development for the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis, tauopathies and chemotherapy-induced peripheral neuropathy (CIPN). The drug candidate acts by targeting histone deacetylase 6 (HDAC6).
Eikonizo Therapeutics overview
Eikonizo Therapeutics is a biotechnology company that develops life-changing therapies by creating brain-penetrant and peripherally restricted small molecules. The company’s lead drug HDAC6 is a selective histone deacetylase-6 inhibitor that treats various neurodegenerative disorders which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, chemotherapy-induced peripheral neuropathy (CIPN), autosomal dominant polycystic kidney disease (ADPKD) and cardiac indications. It works in partnership with Target ALS Foundation, Inc., Alzheimer’s Association, Rainwater Charitable Foundation and National Institutes of Health. Eikonizo Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of EKZ-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
